Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cam-H2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : INKEF Capital
Deal Size : $87.8 million
Deal Type : Series B Financing
Precirix Raises EUR 80m in Series B to Advance Its Pipeline of Precision Radiopharmaceuticals
Details : The proceeds of this financing round will fund the development and expansion of Precirix’ pipeline. More specifically, the company will advance CAM-H2 through its ongoing Phase I/II study and plans to bring additional novel radiopharmaceuticals to the ...
Product Name : Cam-H2
Product Type : Radiolabelled Compounds
Upfront Cash : Undisclosed
March 16, 2022
Lead Product(s) : Cam-H2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : INKEF Capital
Deal Size : $87.8 million
Deal Type : Series B Financing
Lead Product(s) : Cam-H2
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CAM-H2 comprises a single-domain antibody targeting HER2, covalently linked to iodine-131. Single-domain antibodies are ideally suited for targeted delivery of radiation to tumors given their size for the treatment of HER2-positive metastatic cancer.
Product Name : Cam-H2
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
June 10, 2021
Lead Product(s) : Cam-H2
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
